CUTISS closes CHF 56M Series C round and signs agreement with leading EU burn center

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

Tags

CUTISS-denovoSkin

More Like This

PR Newswire associated0

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Dan Coaten (right) presents Dr. Sandra Moritz (center) with the Kerecis Center of Excellence certification. (Photo: Business Wire)

Kerecis Announces First European Center of Excellence for Medical Fish-Skin Technology

T-cell therapy developer, Cbio A/S Unveils 2023 Annual Report Amid Clinical Trial Preparations, Signaling Major Shift to Clinical Stage with DKK40M Financing Secured

Wyss Geneva Spin-Off Clee Medical Secures Seed Financing to Bring Real-Time Vision to Brain Surgery

PR Newswire associated0

Novadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs

MariCell® Solid

Kerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 2026

From Biopsy to Breakthrough, CTIBIOTECH USA™'s Vision for Precision Medicine

Printing the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment Summit

The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of 128 days, enabling unprecedented long-term studies on drug resistance and metastasis . Ultimately, CTIONCOTEST delivers a highly predictive, 100% human-derived ethical alternative to animal testing.

Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care